Bone Biologics Corporation · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-12-09$2.11 RISE2026-03-30$1.08 PEAK2026-04-22$1.41 134d | -48.8% 111d | Missed | Missed | — | — | +30.1% 23d | Missed |
DROP2025-10-09$2.70 RISE2026-02-17$1.12 PEAK2026-04-22$1.41 195d | -58.5% 131d | Missed | Missed | — | — | +25.4% 64d | Missed |
DROP2025-09-04$2.85 RISE2025-12-31$1.45 PEAK2026-01-16$1.78 134d | -49.1% 118d | Missed | Missed | — | — | +22.8% 16d | Missed |
DROP2025-07-23$3.06 RISE2025-11-21$1.33 PEAK2025-12-09$2.11 139d | -56.5% 121d | Missed | Missed | — | — | +58.6% 18d | Missed |
DROP2025-06-23$6.20 RISE2025-09-10$2.00 PEAK2025-09-30$2.79 99d | -67.7% 79d | Missed | Missed | — | — | +39.5% 20d | Missed |
DROP2025-02-03$7.62 RISE2025-04-28$3.96 PEAK2025-06-23$6.20 140d | -48.0% 84d | Missed | Missed | — | — | +56.6% 56d | Missed |
DROP2024-10-21$11.88 RISE2025-03-04$4.76 PEAK2025-05-21$5.47 212d | -59.9% 134d | Missed | Missed | — | — | +15.0% 78d | Missed |
DROP2024-09-26$15.18 RISE2024-12-24$5.40 PEAK2025-02-03$7.62 130d | -64.4% 89d | Missed | Missed | — | — | +41.1% 41d | Missed |
DROP2024-08-02$16.32 RISE2024-09-13$4.80 PEAK2024-09-26$15.18 55d | -70.6% 42d | Missed | Missed | — | — | +216.3% 13d | Missed |
DROP2024-03-13$15.42 RISE2024-07-09$6.60 PEAK2024-08-01$16.32 141d | -57.2% 118d | Missed | Missed | — | — | +147.3% 23d | Missed |
DROP2023-08-10$64.80 RISE2023-12-15$18.19 PEAK2023-12-28$36.00 140d | -71.9% 127d | Missed | Missed | — | — | +97.9% 13d | Missed |
DROP2023-04-18$397.44 RISE2023-08-24$29.76 PEAK2023-11-16$37.44 212d | -92.5% 128d | Missed | Missed | — | — | +25.8% 84d | Missed |
DROP2023-02-15$561.60 RISE2023-03-28$328.32 PEAK2023-04-05$400.32 49d | -41.5% 41d | Missed | Missed | — | — | +21.9% 8d | Missed |
DROP2023-02-15$561.60 RISE2023-03-27$328.32 PEAK2023-04-05$400.32 49d | -41.5% 40d | Missed | Missed | — | — | +21.9% 9d | Missed |
DROP2022-08-23$2,324.16 RISE2022-12-28$273.60 PEAK2023-02-15$561.60 176d | -88.2% 127d | Missed | Missed | — | — | +105.3% 49d | Missed |
1–15 / 20 1 / 2 | |||||||
No scored news yet for a sentiment trend.
The updated shelf life is supported by continued third-party stability data. The additional five months of validated product life is expected to provide greater flexibility in lot sizing and distribution planning as the
Bone Biologics (NASDAQ:BBLG) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.54) by 20.37 percent. This is a 77.6 percent increase over losses of $(1.92) per share from the
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_03032026_BBLG_Sorensen.pdf
By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) is a clinical-stage biotechnology company focused on transforming the multibillion-dollar spine fusion and bone regeneration market through its proprietary orthobiologic technology. At the heart of its platform is a novel recombinant human protein known as NELL-1 , which the company has exclusively
By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) is a clinical-stage biotechnology company focused on transforming the multibillion-dollar spine fusion and bone regeneration market through its proprietary orthobiologic technology. At the heart of its platform is a novel recombinant human protein known as NELL-1 , which the company has exclusively
Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq complianceBURLINGTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today summarized key corporate, scientific, and operational milestones achieved during 2025 and outlined its strategic outlook for 2026. “We executed wit
Milestone advances manufacturing readiness and supports long-term commercialization strategyBURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces it has received confirmation that the shelf life of its rhNELL-1 product has been extended to 24 months, delivering on previously communicated forecasts. The extended shelf life is validated by o
Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ:BBLG, BBLGW))), a developer of orthobiologic products for spine fusion markets, announces it has received confirmation that the shelf life of its
https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_11172025_BBLG_Sorensen.pdf
By Brad Sorensen, CFA NASDAQ:BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) is a company developing products for the spine fusion market and is entering an exciting and crucial time period as human trials have begun and results should be available, at least preliminary data, in the coming year. Given the preclinical studies that we’ve reported on extensively, we are
td class="col-issue">Next Technology Holding Inc.
td class="col-issue">Next Technology Holding Inc.
BURLINGTON, Mass., September 04, 2025--Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that President and Chief Executive Officer Jeffrey Frelick has issued the following letter to stockholders.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BBLG | +0.53% | +10.92% | -8.97% | -75.00% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -2.44% | +16.64% | -5.52% | -87.69% |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-14 | -0.54 | -0.43 | +20.37% |
| 2026-03-02 | -0.34 | -0.63 | -85.29% |
| 2025-11-14 | -1.23 | -0.37 | +69.92% |
| 2025-08-14 | -0.58 | -1.33 | -129.31% |
| 2025-02-26 | -3.90 | -2.88 | +26.15% |
| 2024-11-14 | -3.60 | -14.22 | -295.00% |
| 2024-08-09 | -8.34 | -4.02 | +51.80% |
| 2024-05-14 | -45.60 | -7.86 | +82.76% |
| 2023-11-14 | -145.92 | -29.28 | +79.93% |
| 2023-08-14 | -72.00 | -81.12 | -12.67% |
| 2023-05-15 | -100.80 | -331.20 | -228.57% |
| 2023-03-30 | -324.00 | 144.00 | +144.44% |
| 2022-11-14 | -216.00 | -172.80 | +20.00% |
| 2022-08-11 | -172.80 | -72.00 | +58.33% |
| 2022-05-13 | -288.00 | -100.80 | +65.00% |
| 2022-03-15 | -244.80 | -72.00 | +70.59% |